CEO Timothy Goodnow在2026年3月13日购买了17 225股感官股份, CEO Timothy Goodnow bought 17,225 shares of Senseonics on March 13, 2026, boosting his stake by 2.72%.

2026年3月13日,Senseonics首席执行官蒂莫西·古德诺以每股5.79美元的价格购买了17225股股票,他的股份增长了2.72%至651,243股,价值约377万美元. On March 13, 2026, Senseonics CEO Timothy Goodnow bought 17,225 shares at $5.79 each, boosting his stake by 2.72% to 651,243 shares, worth about $3.77 million. Douglas Roeder主任还收购了17 500股股份,其所有权增加了17.12%。 Director Douglas Roeder also acquired 17,500 shares, increasing his ownership by 17.12%. 该公司的股票在3月16日上升了11.4%至6.28美元,交易量低于平均水平。 The company’s stock rose 11.4% to $6.28 on March 16, with below-average trading volume. 开发Eversense植入式血糖监测系统的Senseonics公司的市值为2.624亿美元,债务与股权比为0.58,分析师的预期是混合的,共识是"中等购买"评级和平均目标价格为22.70美元. Senseonics, which develops the Eversense implantable glucose monitoring system, has a $262.48 million market cap, a debt-to-equity ratio of 0.58, and a mixed analyst outlook with a consensus “Moderate Buy” rating and a $22.70 average price target. 机构投资者持有12.36%的股份。 Institutional investors hold 12.36% of shares.